R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AIHKG: 3696

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Ascletis PharmaHKG: 1672

Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy

Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal
AIHKG: 3696

Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal

Bio-Sincerity UCAS R&D Center Pharma Synthesis
Bio-Sincerity Pharmaceutical TechnologySHE: 301096

Bio-Sincerity UCAS R&D Center Pharma Synthesis

Show More